Predicting treatment for sarcomas and melanomas using patient-derived models
Official title: Q-SAM (Using QPOP to Predict Treatment for Sarcomas and Melanomas)
Run by National Cancer Centre, Singapore · NCT04986748 · Data updated 2026-11-12
This study is trying to see if creating models from tumor samples can help find the best drug combinations for patients with sarcomas and melanomas after their usual treatments haven't worked.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 21 Years to 99 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | National Cancer Centre, Singapore Academic / other |
| Locations | 1 site (Singapore) |
| Status | Recruiting |
| Started | September 8, 2020 |
| Main results expected | October 31, 2028 |
| Study ends | December 31, 2028 |
| Registry record updated | July 1, 2025 |
| Trial ID | NCT04986748 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients diagnosed with sarcoma or melanoma who have at least one tumor lesion suitable for biopsy or resection.
✕Probably not a fit
Patients who do not have a diagnosis of sarcoma or melanoma will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate drug sensitivities in patients with sarcomas and melanomas by creating two- and three-dimensional models from tumor samples. Patients will undergo standard-of-care resections or biopsies, which will be used to generate these models. The study will then perform ex vivo drug testing on these models using a panel of up to 14 drugs known to be effective against these cancers. The goal is to identify effective drug combinations and tailor treatments based on individual patient responses after standard treatments have failed.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized and effective treatment options for patients with sarcomas and melanomas.
How similar studies have gone: While the approach of using patient-derived models for drug testing is gaining traction, this specific application of QPOP in sarcomas and melanomas is relatively novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of sarcoma or melanoma * At least 1 tumour lesion amenable to fresh biopsy or resection * Signed informed consent from patient or legal representative * Able to comply with study-related procedures Exclusion Criteria: * There are no specific exclusion criteria if patients meet the inclusion criteria
Where it's running
-
National Cancer Centre Singapore
Singapore, Singapore Recruiting
Study contacts
- Principal investigator: Valerie Shiwen Yang, BSc, MB BChir, PhD — National Cancer Centre, Singapore
- Study coordinator: Valerie Shiwen Yang, BSc, MB BChir, PhD
- Email: valerie.yang.s.w@singhealth.com.sg
- Phone: +65 6436 8088
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
LRRC15-targeted PET imaging for more precise diagnosis and staging of pancreatic, breast, lung, sarcoma and head-and-neck cancers
This project tests whether an LRRC15-targeted PET scan can better detect and stage LRRC15-expressing cancers and measures how the tracer behaves in healthy adults.
-
Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors
This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.
-
Super1 TCR-T for NY-ESO-1–positive advanced solid tumors
This trial tests whether a single infusion of Super1 TCR-T can help people with advanced sarcoma, lung cancer, or melanoma whose tumors are HLA-A*02 positive and express NY-ESO-1.
-
IDOV-Immune for advanced solid tumors
This trial will try a single IV infusion of an engineered oncolytic vaccinia virus called IDOV-Immune in adults with advanced solid tumors that no longer respond to standard treatments.
-
Using Riluzole to Help Breast Cancer Survivors with Cognitive Issues
This study is testing if the medication riluzole can help breast cancer survivors who are having trouble with thinking and memory feel better.
-
Evaluating comprehensive molecular testing for advanced cancer patients
This study is testing whether a new genetic test can help doctors choose better treatments for patients with advanced cancers like breast cancer and melanoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.